Navigation Links
Encorium Reports Second Quarter 2009 Financial Results
Date:8/24/2009

by severance and other costs of $202 thousand.

Selling, general, and administrative expenses (SG&A) decreased by 12% to $2.2 million, or 49.9% of net revenue, for the three months ended June 30, 2009, compared to $2.5 million, or 43% of net revenue, for the three months ended June 30, 2008. The decrease in SG&A was due primarily to approximately $178 thousand of favorable currency fluctuations and reduction in staff and facility costs in the Company's U.S. operations, partially offset by higher professional fee associated with the sale of the U.S. business.

Depreciation and amortization expense decreased 61.25% to $93,000 for the three months ended June 30, 2009 from $240,000 for the three months ended June 30, 2009 primarily as a result of certain intangible assets acquired as part of the Encorium Oy (formerly Remedium) acquisition being fully amortized.

Loss from continued operations increased by $604,000 for the three months to $1.3 million or $(0.06) per diluted share for the second quarter of 2009, from a net loss of $665,000, or $(0.03) per diluted share in the second quarter of 2008.

Financial Position

Encorium's balance sheet at June 30, 2009 reflected cash and cash equivalents of $838,696 and stockholders' equity of $1.8 million. The Company's latest financials have been prepared on a going concern basis. As previously disclosed, Encorium's independent registered public accounting firm reported that the Company's audited consolidated financial statements for the fiscal year ended December 31, 2008, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 27, 2009, contains a paragraph that indicates that, while the Company's financial statements have been prepared on a going concern basis, there is substantial doubt about its ability to continue as a going concern, and that no adjustments have been mad
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
4. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
5. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
6. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
7. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
8. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
9. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. QMed, Inc. Reports July Medicare SNP Enrollments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... has announced the addition of Jain PharmaBiotech,s new ... Companies" to their offering. This ... development of sequencing technologies, and their applications. Current ... as companies developing them. Various applications of sequencing ...
(Date:9/2/2015)... 02, 2015 Research and ... Jain PharmaBiotech,s new report "Gene Therapy - Technologies, ... The markets for gene therapy are difficult to estimate ... and it is marketed in China ... the years 2014-2024. The estimates are based on epidemiology ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... , September 2, 2015 ... BOLT) ("BioLight" or the "Company"), a firm that ... ophthalmology and cancer diagnostics, announced today that presentations ... glaucoma will be delivered at the Ophthalmology Futures ... European Society of Cataract & Refractive Surgeons ("ESCRS"), ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... VRML ) announced that on February 22, 2008 it ... indicated the Company is not in,compliance with Marketplace Rule ... $2,500,000 in stockholders, equity; (ii) $35,000,000 in market,value of ... continuing,operations for the most recently completed fiscal year or ...
... SAN DIEGO, Feb. 27 Arena Pharmaceuticals,Inc. (Nasdaq: ... quarter,and full year ended December 31, 2007., Total ... million,compared to $4.7 million in the fourth quarter of ... 2007 were $19.3 million, compared to $30.6,million in the ...
... Feb. 27 DARA BioSciences(TM),(Nasdaq: DARA ) announced ... Board of Directors. Mr. Cochrane was appointed to fill ... and Compensation Committees.,The appointment was effective February 21, 2008., ... Franco, Sr.,commented, "We are pleased that Haywood has joined ...
Cached Biology Technology:Vermillion Receives NASDAQ Notice of Non-Compliance 2Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 2Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 3Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 4Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 5Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 6Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 7Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 8Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 9Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 10Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 11DARA BioSciences, Inc. Announces Appointment of New Director to Board 2
(Date:8/20/2015)... OXFORD, CT ., Aug. 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... wallet, announces it has joined The Smart Card Alliance ... the Smart Card Alliance and the Smart Card Alliance ... and visibility to industry peers and thought leaders promoting ...
(Date:8/18/2015)... N.J. , Aug. 18, 2015 /PRNewswire/ ... a key contributor to the Submission Content ... by IRISS, a non-profit forum. Dedicated to the ... provides a neutral platform for industry, vendors, ... share information and work towards a standard ...
(Date:8/17/2015)... Conn. , Aug. 17, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... its new sales campaign for Q4 2015. The new ... marketing team consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ... Marketing Group is a leader in retail driven marketing ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... finding on the brain's role in controlling appetite and ... have shown that reducing levels of fatty acids in ... Their results suggest that restoring fatty-acid levels in the ... The study, published in the January 15th on-line edition ...
... 17 and mouse chromosome 11 offers unique insights into ... a Baylor College of Medicine researcher who participated in ... Nature. , The work represents the first time that ... said Dr. James R. Lupski, vice chair and professor ...
... emit a cocktail of scents when they are attacked by ... cotton leaf worm. , Parasitic wasps use these plant scents ... so that their offspring can feed on the caterpillar. ... from its attacker. In the case of corn, only one ...
Cached Biology News:Study by Einstein researchers could lead to a novel strategy for treating obesity 2Mouse to man: The story of chromosomes 2New possibilities to fight pests with biological means 2
Syd-2 (cL-19)...
... for isolation and affinity purification of ... peptides. Hydrophobic, monodisperse magnetic particles (2.8 ... groups, further surface activation is not ... with optimal orientation for affinity purification ...
ZO-2 (H-110)...
p-Bcl-2 (Thr 74)...
Biology Products: